Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis c treatment with peginterferon alpha-2b plus ribavirin to hcv genotype and early viral response: A Decision analysis based on german guidelines

PharmacoEconomics

Volumn 27, Issue 4, 2009, Pages 341-354

  Siebert, Uwe ^a,b,c   Sroczynski, Gaby ^a,b   Aidelsburger, Pamela ^d   Rossol, Siegbert ^a,e   Wasem, Jürgen ^d   Manns, Michael P ^f   McHutchison, John G ^g   Wong, John B ^h  

^a UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g SCRIPPS CLINIC   (United States)

^h TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; ASCITES; BODY WEIGHT; CAUSE OF DEATH; CHRONIC HEPATITIS; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG WITHDRAWAL; FEMALE; GENOTYPE; GERMANY; HEALTH ECONOMICS; HEALTH STATUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS HEPATITIS;

ADULT; ANTIVIRAL AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; GERMANY; GUIDELINES AS TOPIC; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIFE EXPECTANCY; MALE; MARKOV CHAINS; POLYETHYLENE GLYCOLS; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN; SENSITIVITY AND SPECIFICITY;

EID: 67649839932     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/00019053-200927040-00006     Document Type: Article

References (65)

1. Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127 (10): 855-65
2. Wong JB, Poynard T, Ling MH, et al. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with riba-virin as initial treatment of chronic hepatitis C. Inter- national Hepatitis Interventional Therapy Group. Am J Gastroenterol 2000; 95 (6): 1524-30
3. Younossi ZM, Singer ME, McHutchison JG, et al. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30 (5): 1318-24
4. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess 2000; 4 (33): 1-67
5. Stein K, Rosenberg W, Wong J. Cost effectiveness of combination therapy for hepatitis C: a decision analytic model. Gut 2002; 50 (2): 253-8
6. Buti M, Casado MA, Fosbrook L, et al. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J Hepatol 2000; 33 (4): 651-8
7. Sennfalt K, Reichard O, Hultkrantz R, et al. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001; 36 (8): 870-6
8. Sagmeister M, Wong J, Mullhaupt B, et al. A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol 2001; 13 (5): 483-8
9. Siebert U, Sroczynski G, Rossol S, et al. Cost-effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425-32
10. Sullivan SD, Craxi A, Alberti A, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitisC.Pharmacoeconomics 2004; 22 (4): 257-65
11. Buti M, Medina M, Casado MA, et al. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17 (5): 687-94
12. Siebert U, Sroczynski G, with the collaboration of the German Hepatitis C Model (GEHMO) Group. Antiviral therapy in patients with chronic hepatitis C in Germany: clinical and economic evaluation of the initial combination therapy with interferon/peginterferon and ribavirin. Health Technology Assessment. Vol. 8. HTA series of the German Institute for Medical Documentation and Information, commissioned by the Federal Ministry of Health and Social Security. Cologne: German Institute for Medical Documentation and Information (DIMDI), 2003
13. Siebert U, Sroczynski G. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Tech Assess Health Care 2004; 21 (1): 55-65
14. Shepherd J, Brodin H, Cave C, et al. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004; 8 (39): iii-iv, 1-125
15. Shepherd J, Brodin HF, Cave CB, et al. Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int J Technol Assess Health Care 2005; 21 (1): 47-54
16. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C. 2002: June 10-12, 2002. Hepatology 2002; 36 (5 Suppl. 1): S3-20
17. Seeff LB, Hoofnagle J. National Institutes of Health Consensus Development Conference: management of hepatitis C. 2002. Hepatology 2002; 36 (5 Suppl. 1): S1-2
18. Zeuzem S. Standard treatment of acute and chronic hepatitis C. Z Gastroenterol 2004; 42 (8): 714-9
19. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3: 419-58
20. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38
21. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1 (5): 431-5
22. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading, and staging. Hepatology 1994; 19: 1513-20
23. Yousuf M, Nakano Y, Sodeyama T, et al. Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up. Scand J Gastroenterol 1992; 27: 812-6
24. Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992; 16: 273-81
25. Mattsson L. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver 1993; 13: 274-8
26. Takahashi M, Yamada G, Miyamoto R, et al. Natural course of chronic hepatitis C. Am J Gastroenterol 1993; 88 (2): 240-3
27. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112 (2): 463-72
28. Salerno F, Borroni G, Moser P, et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. Am J Gastroenterol 1993; 88 (4): 514-9
29. Anonymous. Sclerotherapy for male alcoholic cirrhotic patients who have bled from esophageal varices: results of a randomized, multicenter clinical trial. The Veterans Affairs Cooperative Variceal Sclerotherapy Group. Hepatology 1994; 20 (3): 618-25
30. Christensen E, Krintel JJ, Hansen SM, et al. Prognosis after the first episode of gastrointestinal bleeding or coma in cirrhosis: survival and prognostic factors. Scand J Gastroenterol 1989; 24 (8): 999-1006
31. Ascher N, Lake J, Emond J, et al. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994; 20 (1 Pt 2): 24S-7S
32. Detre K, Belle S, Lombarddero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev 1996; 2: 219-28
33. Kilpe V, Krakauer H, Wren R. An analysis of liver transplant experience from 37 transplant centers as reported to Medicare. Transplantation 1993; 56 (3): 554-61
34. Fischer-Frohlich CL. Organ transplantation in the Federal Republic of Germany and in Europe from a medical perspective: an evaluation of the situation [in German]. In: Landeszentrale fur politische Bildung Baden-Wurttemberg, editor. Organentnahme und Transplantation-im Span-nungsfeld zwischen Ethik und Gesetz. Bad Urach/Stuttgart, 1997: 7-28
35. Berg J, Bechstein WO, Mueller A, et al. Lebertransplantation. Internist (Berl) 1998; 39: 1237-45
36. Deutsche Stiftung Organtransplantation (DSO). Figures and data: donated and transplanted organs 1992-2000 [online]. Available from URL: http://www.dso.de/ [Accessed 2002 Jan 30]
37. Federal Statistical Office Germany. Life tables for Germany 2003-2005 [online]. Available from URL: http://www.des tatis.de/2006 [Accessed 2007 Feb 27]
38. Manns M, McHutchison J, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-65
39. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York: Oxford University Press, 1997
40. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
41. Siebert U, Ravens-Sieberer U, Greiner W, et al. Patientbased health-related quality of life in different health stages of chronic hepatitis C [abstract]. Hepatology 2001; 44 (2): 222A
42. Siebert U, Ravens-Sieberer U, Greiner W, et al. Performance of different utility assessment methods in chronic hepatitis C patients. In: Kind P, Macran S, editors. Proceedings of the 19th Plenary Meeting of the EuroQol Group 13th-14th September 2002 Discussion Papers. York: Centre for Health Economics, University of York, 2003: 175-84
43. Heckerling PS, Verp MS. Amniocentesis or chorionic villus sampling for prenatal genetic testing: a decision analysis. J Clin Epidemiol 1991; 44 (7): 657-70
44. Kuppermann M, Shiboski S, Feeny D, et al. Can preference scores for discrete states be used to derive preference scores for an entire path of events? An application to prenatal diagnosis. Med Decis Making 1997; 17 (1): 42-55
45. German Red List [database on the Internet]. PegIntron, p. 10, 2006 [online]. Available from URL: http://www. rote-liste.de [Accessed 2009 Mar 4]
46. Anonymous. Gebührenordnung für Ärzte (GOÄ) [online]. Available from URL: http://www.e-bis.de/goae/default Frame.htm 2002 [Accessed 2002 Jul 27]
47. Kassenärztliche Bundesvereinigung. Einheitlicher BewertungsmaXstab (EBM) [online]. Available from URL: http://www.kbv.de/8156.html, 2002 [Accessed 2002 Jul 27]
48. Federal Statistical Office Germany. Price index for physicians, hospitals and other health care services. Wiesbaden: Statistisches Bundesamt, 2003
49. Maddrey WC. Safety of combination interferon alfa-2b/ ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19Suppl. 1: 67-75
50. Welte R, Leidl R. Übertragung der Ergebnisse ökonomischer Evaluationsstudien aus dem Ausland auf Deutschland: Probleme und Lösungsansätze. Ansätze und Methoden der ökonomischen Evaluation - eine internationale Perspektive. In: Leidl R, Schulenburg JM, Wasem J, editors. Baden-Baden: Nomos, 1999; 81-112
51. Drummond MF, Bloom BS, Carrin G, et al. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care 1992; 8: 671-82
52. Baltussen B, Ament A, Leidl R. Making cost assessments based on RCTs more useful to decision-makers. Health Policy 1996; 37: 163-83
53. Anonymous. Lauer-Taxe Arzneimittelverzeichnis: Apothekeneinkaufs- und verkaufspreise [online]. Available from URL: http://www.lauer-fischer.de/LF/ Seiten/Produkte/ Online-Dienste/Lauer-Taxe%20online.aspx 2002 [Accessed 2002 Mar 12]
54. Luce BR, Manning WG, Siegel JE, et al. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 176-213
55. Weinstein C, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276 (15): 1253-8
56. Dore G, Freeman A, Law M, et al. Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol 2002; 17 (4): 423-30
57. Freeman A, Dore G, Law M, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepato-logy 2001; 34 (4): 809-16
58. Bonis PA, Ioannidis JP, Cappelleri JC, et al. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics. Hepatology 1997; 26 (4): 1035-44
59. Reichard O, Glaumann H, Fryden A, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995; 21 (4): 918-22
60. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36 (5 Suppl.): S47-56
61. Weinstein MC. High-priced technology can be good value for money. Ann Intern Med 1999; 130 (10): 857-8
62. Wong JB, Sonnenberg FA, Salem DN, et al. Myocardial revascularization for chronic stable angina: analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med 1990; 113 (11): 852-71
63. Wong JB, Davis GL, McHutchison JG, et al. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 2003; 98 (11): 2354-62
64. Siebert U. When should decision-analytic modeling be used in the economic evaluation of health care? Eur J Health Econ 2003; 4 (3): 143-50
65. Siebert U. Using decision-analytic modelling to transfer international evidence from health technology assessment to the context of the German Health Care System. A HTA Methods Report. (Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health and Social Security). Koln: DIMDI, 2005